Pyxis Oncology, Inc. $PYXS Holdings Lowered by American Century Companies Inc.

Key Takeaways:

• American Century reduced its Pyxis Oncology position by 91.2%.
• It sold 273,584 shares in the first quarter.
• The institutional investor now holds 26,353 shares.
• The data comes from the firm’s recent SEC 13F filing.

Major Stake Reduction

American Century Companies Inc. slashed its holdings in Pyxis Oncology, Inc. (NASDAQ: PYXS) by 91.2% during the first quarter of this year. According to the institutional investor’s recent 13F filing with the Securities and Exchange Commission (SEC), more than 273,000 shares were sold during the period.

Filing Details

This large-scale sell-off was revealed in official documents filed with the SEC. The move highlights American Century Companies Inc.’s significant pullback from Pyxis Oncology at a time when quarterly repositioning can often signal changing market sentiments or portfolio strategies.

Remaining Shares

Following these transactions, American Century Companies Inc. now holds 26,353 shares of Pyxis Oncology. Though the original percentage drop is substantial, the company remains an investor in Pyxis, whose shares trade on NASDAQ under the ticker symbol PYXS.

No Added Details

Beyond the filing itself, no further explanation was provided for the reduction. Pyxis Oncology has not released a statement on the matter, and any additional speculation as to the reasons behind this move remains outside the scope of the disclosed data.

Looking Forward

As the numbers stand, American Century Companies Inc.’s decision places Pyxis Oncology in a spotlight for investors watching institutional moves. The impact of such a dramatic change may shape near-term conversations around the company, but details regarding the motivation remain confined to the 13F filing and official disclosures.